SCHEMBL456895

SCHEMBL456895

CC(C)C1CCCCN1C(C)C

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12566547 1.00 P2RX7 (0.30) P2RX7
SCHEMBL12566879 1.00 P2RX7 (0.30) P2RX7
SCHEMBL12546154 0.98 P2RX7 (0.30) P2RX7
SCHEMBL18737218 0.98 P2RX7 (0.30) P2RX7
SCHEMBL20259597 0.98 P2RX7 (0.30) P2RX7
SCHEMBL24677462 0.98 P2RX7 (0.30) P2RX7
SCHEMBL20259642 0.98 P2RX7 (0.30) P2RX7
SCHEMBL23766519 0.98 P2RX7 (0.30) P2RX7
SCHEMBL840278 0.98 P2RX7 (0.30) P2RX7
SCHEMBL839891 0.93 AR (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105585644-A Ziegler-Natta catalyst component for olefin polymerization and catalyst thereof PETROCHINA CO LTD 2016-05-18 CN claimed
EP-0016582-B1 ZIEGLER-TYPE CATALYST COMPOSITION EXXON RESEARCH AND ENGINEERING COMPANY (US) 1984-10-03 EP claimed
EP-0016581-B1 ZIEGLER TYPE CATALYST COMPOSITION EXXON RESEARCH AND ENGINEERING COMPANY (US) 1984-08-08 EP claimed
EP-0015763-B1 ZIEGLER TYPE CATALYST SYSTEM EXXON RESEARCH AND ENGINEERING COMPANY (US) 1984-05-16 EP claimed
EP-0035889-B1 ALKYL-METAL COCATALYST EXXON RESEARCH AND ENGINEERING COMPANY (US) 1984-05-02 EP claimed
US-20240226113-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-07-11 US disclosed
WO-2024107763-A1 N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF UNIVERSITY OF ZURICH (CH) 2024-05-23 WO disclosed
US-20240067642-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-02-29 US disclosed
US-20240067642-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-02-29 US disclosed
US-20240024318-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
WO-2023247590-A1 TRIAZOLOPYRIDINE AND BENZOISOXAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2023-12-28 WO disclosed
EP-0344755-B2 Components and catalysts for the polymerization of olefins MONTELL NORTH AMERICA INC (US) 1997-09-10 EP disclosed
CN-1035385-C Process for preparing stabilized polyolefins HIMONT INC (US) 1997-07-09 CN disclosed
CN-1074222-A Process for preparing stabilized polyolefins and products thereof HIMONT INC (US) 1993-07-14 CN disclosed
EP-0267576-B1 COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF ALPHA-OLEFINS TO STEREOREGULAR POLYMERS HAVING NARROW MOLECULAR WEIGHT DISTRIBUTION Himont Incorporated (US) 1992-05-27 EP disclosed
EP-0376145-A2 Method for producing a stereoregular polyolefin Tosoh Corporation (JP) 1990-07-04 EP disclosed
EP-0373660-A2 Propylene polymer compositions having good transparency and improved impact resistance MONTELL NORTH AMERICA INC. (US) 1990-06-20 EP disclosed
EP-0344755-A1 Components and catalysts for the polymerization of olefins MONTELL NORTH AMERICA INC. (US) 1989-12-06 EP disclosed
EP-0267576-A2 Components and catalysts for the polymerization of alpha-olefins to stereoregular polymers having narrow molecular weight distribution Himont Incorporated (US) 1988-05-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024318-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCA2, SMARCC2 P2RX7 3649/4885
US-20240226113-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TP53, HRAS, KRAS P2RX7 3782/4885
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 P2RX7 3896/4885
US-20240067642-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 P2RX7 1952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.